you are viewing a single comment's thread.
ARC did what you wanted to happen. No significant difference in LT from Cypher and BMS. You state we need to take a step back because of the uncertainty of stenting because of thrombosis (DES and BMS).Stents have been used for well over 10-12 years. How much futher back do you want to go. I think Taxol is a terrible drug for CAD, and the FDA will analyse it in the ARC terms. Taxus, as a first generation DES, will be shown for the holes you claim eventually. Cypher is much cleaner.CABG will always have its place, but continue to dimish in case volume. Patients want less invasive, and you can't blame them.